ISO 10993-5 Cytotoxicity testing

We offer the ISO 10993-5 Cytotoxicity in-vitro testing which evaluates the ability of a medical device to elicit a cytotoxic response in mammalian cells. It is a rapid, animal-free and sensitive test which is critical to any medical devices' technical file.

What is ISO10993-5 Cytotoxicity testing?

Cytotoxicity testing is a fundamental first step in demonstrating the biological safety of medical devices. Regulatory authorities require biological endpoints which prove that materials in contact with human tissue do not cause cell damage or death.

As re-enforced by the ISO 10993-1, cytotoxicity testing is used as an early indicator to identify potentially harmful materials prior to costly downstream testing such as in vivo testing (animal studies).

By working with Test Labs and our team of experts on toxicological assessments, the ISO 10993-5 testing supports faster regulatory approval, reduced development risk, and avoidance of animal testing.

The ISO 10993-5 testing evaluates whether extracts or direct contact with a medical device result in reduced cell viability, altered cell morphology, or cell lysis (death). A test item is considered cytotoxic if cell viability is below 70% compared to the negative control.

Cytotoxicity testing is applicable to any medical device with direct or indirect contact with the human body, including: implantable devices and components; catheters, tubing, and wound dressings; surgical instruments, dental materials and devices; external communicating and surface-contacting devices; raw materials, coatings, and adhesives used in device manufacture.

Biological Evaluation Plan

BEP establishes your product testing requirements. It also helps to prevent unnecessary testing studies.

ISO 10993-5 Cytotoxicity test

Cytotoxicity testing using the MTT cytotoxicity assay, this test measures the viability of the cells via targeting the metabolic activity of the cell using the L929 cell line.

Biological Evaluation Report

Your report will be issued with in two weeks of experimental phase completion, fully compliant with GLP requirements

ISO 10993-5 Cytotoxicity testing

We perform ISO 10993-5 Cytotoxicity studies in compliance with the Principles of Good Laboratory Practice (GLP). GLP is a defined set of Principles designed to be implemented within a quality system of a test facility conducti ng non-clinical health and environmental safety studies intended for regulatory submission. These principles outline how studies should be planned, performed, monitored, recorded, archived, and reported with the aim to harmonise the way in which test facilities work.

The GLP Principles were published for test facilities to comply with to ensure the integrity, quality, consistency, and reliability of data that is produced.
The GLP regulations require that “regulatory studies” to demonstrate the safety or properties where the data is intended for submission must be performed at a test facility that is a member of the respective national compliance monitoring programme. As a member of this programme test facilities are inspected on a regular basis as an assessment of conformity.

Frequently Asked Questions

In vitro biocompatibility testing – Skin irritation: Everything You Need to Know

In vitro means ‘in glass’ which essentially refers to testing that occurs in glass vessels, instead of in a human or animal

A Guide to Good Laboratory Practice (GLP): Everything You Need to Know

GLP is a defined set of principles to be implemented in a QMS by an organisation completing non-clinical studies

Medical Device Biocompatibility Testing: Everything You Need to Know

Biocompatibility testing is fundamental in deciphering if a medical device is safe to use when introducing a medical device into t...

Contact Us:

Strong foundations are built with robust Quality Management Systems